CAMBRIDGE, Mass. & MIAMI--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, announced today that they have entered into a collaboration agreement for the continued advancement of ALN-AAT, a subcutaneously administrated RNAi therapeutic in development for the treatment of alpha-1 antitrypsin (AAT) deficiency-associated liver disease. TAP’s mission is to work with patients, academia, pharmaceutical and biotech companies, and public health organizations in the pursuit of cures and therapies for chronic obstructive pulmonary disease (COPD) and liver disease caused by AAT deficiency. TAP is partially funding research activities for ALN-AAT. Detailed financial terms of the research agreement were not disclosed. Alnylam remains on track to file an investigational new drug (IND) application for this program in mid-2015.
Help employers find you! Check out all the jobs and post your resume.
